t-MTUCB
Canine sEH IC50 2.0 +/- 0.3 ng/mL (compared to 0.4 for t-TUCB
General
Type : Urea derivative,Multitarget
Chemical_Nomenclature : trans-4-{4-[3-methyl-3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid
Canonical SMILES : C1=CC(=CC=C1OC(F)(F)F)N(C(N(C2CCC(CC2)OC3=CC=C(C=C3)C(O[H])=O)[H])=O)C.C([H])([H])([H])[H].C
InChI : InChI=1S\/C22H23F3N2O5\/c1-27(16-6-12-19(13-7-16)32-22(23,24)25)21(30)26-15-4-10-18(11-5-15)31-17-8-2-14(3-9-17)20(28)29\/h2-3,6-9,12-13,15,18H,4-5,10-11H2,1H3,(H,26,30)(H,28,29)
InChIKey : JSTOWLAYLPNZNS-UHFFFAOYSA-N
Other name(s) : EC3039
MW : 452.43
Formula : C22H23F3N2O5
CAS_number :
PubChem :
UniChem : JSTOWLAYLPNZNS-UHFFFAOYSA-N
IUPHAR :
Wikipedia :
Target
Families : t-MTUCB ligand of proteins in family: Epoxide_hydrolase
Stucture :
Protein : human-EPHX2 || mouse-hyes
References (2)
| Title : Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis - McReynolds_2019_Front.Pharmacol_10_533 |
| Author(s) : McReynolds CB , Hwang SH , Yang J , Wan D , Wagner K , Morisseau C , Li D , Schmidt WK , Hammock BD |
| Ref : Front Pharmacol , 10 :533 , 2019 |
| Abstract : McReynolds_2019_Front.Pharmacol_10_533 |
| ESTHER : McReynolds_2019_Front.Pharmacol_10_533 |
| PubMedSearch : McReynolds_2019_Front.Pharmacol_10_533 |
| PubMedID: 31214021 |
| Title : Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB - Wecksler_2014_Anticancer.Drugs_25_433 |
| Author(s) : Wecksler AT , Hwang SH , Wettersten HI , Gilda JE , Patton A , Leon LJ , Carraway KL, 3rd , Gomes AV , Baar K , Weiss RH , Hammock BD |
| Ref : Anticancer Drugs , 25 :433 , 2014 |
| Abstract : Wecksler_2014_Anticancer.Drugs_25_433 |
| ESTHER : Wecksler_2014_Anticancer.Drugs_25_433 |
| PubMedSearch : Wecksler_2014_Anticancer.Drugs_25_433 |
| PubMedID: 24525589 |